Major Depressive Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Major Depressive Disorder stocks.

Major Depressive Disorder Stocks Recent News

Date Stock Title
May 21 LLY Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
May 21 AZN AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
May 21 AZN European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030
May 21 LLY IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
May 21 LLY If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
May 21 BDRX Biodexa rallies 80% on positive Phase 2 data for eRapa
May 21 LLY Lilly partners with Aktis, deepening radiopharma investment
May 21 LLY Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds
May 21 LLY Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
May 21 BDRX Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
May 21 AZN AstraZeneca sets sights on $80B in revenue by 2030
May 21 AZN AstraZeneca projects $80B in revenue by 2030
May 21 LLY More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
May 21 AZN AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
May 21 LLY Eli Lilly’s tirzepatide cleared for diabetes treatment in China
May 21 AZN Trending tickers: Trump Media, Palo Alto, AstraZeneca and Kingfisher
May 21 AZN AstraZeneca to establish $1.5bn ADC production site in Singapore
May 21 LLY Eli Lilly's diabetes drug tirzepatide gets approval in China
May 21 AZN Lowe's, Macy's, Xpeng rise premarket; Palo Alto, Zoom fall
May 21 AZN AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
Major Depressive Disorder

Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause. People may also occasionally have false beliefs or see or hear things that others cannot. Some people have periods of depression separated by years in which they are normal, while others nearly always have symptoms present. Major depressive disorder can negatively affect a person's personal life, work life, or education, as well as sleeping, eating habits, and general health. Between 2–8% of adults with major depression die by suicide, and about 50% of people who die by suicide had depression or another mood disorder.The cause is believed to be a combination of genetic, environmental, and psychological factors. Risk factors include a family history of the condition, major life changes, certain medications, chronic health problems, and substance abuse. About 40% of the risk appears to be related to genetics. The diagnosis of major depressive disorder is based on the person's reported experiences and a mental status examination. There is no laboratory test for major depression. Testing, however, may be done to rule out physical conditions that can cause similar symptoms. Major depression is more severe and lasts longer than sadness, which is a normal part of life. The United States Preventive Services Task Force (USPSTF) recommends screening for depression among those over the age 12, while a prior Cochrane review found that the routine use of screening questionnaires have little effect on detection or treatment.Typically, people are treated with counseling and antidepressant medication. Medication appears to be effective, but the effect may only be significant in the most severely depressed. It is unclear whether medications affect the risk of suicide. Types of counseling used include cognitive behavioral therapy (CBT) and interpersonal therapy. If other measures are not effective, electroconvulsive therapy (ECT) may be considered. Hospitalization may be necessary in cases with a risk of harm to self and may occasionally occur against a person's wishes.Major depressive disorder affected approximately 216 million people (3% of the world's population) in 2015. The percentage of people who are affected at one point in their life varies from 7% in Japan to 21% in France. Lifetime rates are higher in the developed world (15%) compared to the developing world (11%). It causes the second most years lived with disability, after lower back pain. The most common time of onset is in a person's 20s and 30s. Females are affected about twice as often as males. The American Psychiatric Association added "major depressive disorder" to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980. It was a split of the previous depressive neurosis in the DSM-II, which also encompassed the conditions now known as dysthymia and adjustment disorder with depressed mood. Those currently or previously affected may be stigmatized.

Browse All Tags